Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21322) 21322
Publication (1028) 1028
Newsletter (180) 180
Book Review (74) 74
Magazine Article (24) 24
Book Chapter (23) 23
Newspaper Article (23) 23
Dissertation (7) 7
Conference Proceeding (5) 5
Transcript (4) 4
Web Resource (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18818) 18818
female (11864) 11864
male (11720) 11720
antineoplastic combined chemotherapy protocols - therapeutic use (11668) 11668
vincristine - administration & dosage (11041) 11041
middle aged (8475) 8475
adult (8039) 8039
cyclophosphamide - administration & dosage (7320) 7320
oncology (6854) 6854
doxorubicin - administration & dosage (6683) 6683
aged (6318) 6318
chemotherapy (5470) 5470
vincristine - therapeutic use (5309) 5309
prednisone - administration & dosage (5093) 5093
vincristine (4846) 4846
index medicus (4678) 4678
adolescent (4080) 4080
cyclophosphamide - therapeutic use (3633) 3633
treatment outcome (3570) 3570
antineoplastic combined chemotherapy protocols - administration & dosage (3538) 3538
combined modality therapy (3491) 3491
hematology (3482) 3482
prognosis (3324) 3324
child (3146) 3146
cancer (3051) 3051
doxorubicin - therapeutic use (3006) 3006
antineoplastic combined chemotherapy protocols - adverse effects (2986) 2986
prednisone - therapeutic use (2861) 2861
vincristine - adverse effects (2478) 2478
child, preschool (2412) 2412
methotrexate - administration & dosage (2393) 2393
remission induction (2207) 2207
etoposide - administration & dosage (2174) 2174
cyclophosphamide (2075) 2075
retrospective studies (1965) 1965
neoplasm staging (1947) 1947
follow-up studies (1921) 1921
rituximab (1919) 1919
bleomycin - administration & dosage (1834) 1834
lymphoma, large b-cell, diffuse - drug therapy (1827) 1827
doxorubicin (1802) 1802
disease-free survival (1798) 1798
drug therapy, combination (1798) 1798
lymphoma, non-hodgkin - drug therapy (1796) 1796
survival rate (1733) 1733
therapy (1627) 1627
infant (1586) 1586
aged, 80 and over (1583) 1583
survival analysis (1491) 1491
procarbazine - administration & dosage (1477) 1477
cyclophosphamide - adverse effects (1475) 1475
hodgkin disease - drug therapy (1472) 1472
lymphomas (1450) 1450
animals (1433) 1433
time factors (1424) 1424
drug administration schedule (1421) 1421
doxorubicin - adverse effects (1392) 1392
antineoplastic agents - therapeutic use (1384) 1384
prednisolone - administration & dosage (1337) 1337
survival (1318) 1318
cisplatin - administration & dosage (1293) 1293
care and treatment (1242) 1242
pediatrics (1230) 1230
radiotherapy (1209) 1209
prednisone - adverse effects (1193) 1193
non-hodgkins-lymphoma (1191) 1191
cytarabine - administration & dosage (1152) 1152
children (1111) 1111
lung neoplasms - drug therapy (1070) 1070
antineoplastic combined chemotherapy protocols (1036) 1036
methotrexate - therapeutic use (1004) 1004
antineoplastic agents - administration & dosage (996) 996
young adult (989) 989
lymphoma (968) 968
prednisone (962) 962
vincristine - pharmacology (949) 949
prospective studies (944) 944
dexamethasone - administration & dosage (938) 938
dactinomycin - administration & dosage (928) 928
clinical trials as topic (926) 926
risk factors (912) 912
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (891) 891
lymphoma, large b-cell, diffuse - pathology (876) 876
medicine & public health (864) 864
tumors (859) 859
antibodies, monoclonal, murine-derived (845) 845
etoposide (843) 843
recurrence (823) 823
lymphoma - drug therapy (807) 807
dacarbazine - administration & dosage (793) 793
dose-response relationship, drug (771) 771
trial (769) 769
leukemia (765) 765
pharmacology & pharmacy (765) 765
mechlorethamine - administration & dosage (744) 744
surgery (738) 738
mice (728) 728
medicine, general & internal (718) 718
research (713) 713
analysis (706) 706
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18346) 18346
Japanese (1087) 1087
German (470) 470
French (390) 390
Chinese (348) 348
Spanish (254) 254
Russian (237) 237
Polish (179) 179
Italian (95) 95
Hungarian (28) 28
Portuguese (25) 25
Czech (17) 17
Dutch (17) 17
Hebrew (11) 11
Korean (11) 11
Croatian (10) 10
Danish (10) 10
Serbian (7) 7
Finnish (5) 5
Turkish (5) 5
Ukrainian (5) 5
Bulgarian (4) 4
Romanian (4) 4
Lithuanian (2) 2
Swedish (2) 2
Bosnian (1) 1
Norwegian (1) 1
Persian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high‐risk grade 2 glioma: An analysis of the National Cancer Data Base
by Jhaveri, Jaymin and Liu, Yuan and Chowdhary, Mudit and Buchwald, Zachary S and Gillespie, Theresa W and Olson, Jeffrey J and Voloschin, Alfredo D and Eaton, Bree R and Shu, Hui‐Kuo G and Crocker, Ian R and Curran, Walter J and Patel, Kirtesh R
Cancer, ISSN 0008-543X, 03/2018, Volume 124, Issue 6, pp. 1169 - 1178
BACKGROUND The addition of chemotherapy to adjuvant radiotherapy (chemotherapy and radiation therapy [CRT]) improves overall survival (OS) for patients with... 
overall survival | radiotherapy | National Cancer Data Base (NCDB) | grade 2 glioma | chemotherapy | low‐grade glioma | low-grade glioma | SURVIVAL | OLIGODENDROGLIOMA | LOMUSTINE | RANDOMIZED-TRIAL | TEMOZOLOMIDE CHEMOTHERAPY | PHASE-II TRIAL | THERAPY | ONCOLOGY | PLUS PROCARBAZINE | VINCRISTINE | Chemoradiotherapy - methods | Glioma - mortality | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | Male | Treatment Outcome | Young Adult | Neoplasm Grading | Time Factors | Registries - statistics & numerical data | Glioma - pathology | Brain Neoplasms - therapy | Glioma - therapy | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Care and treatment | Chemotherapy | Usage | Brain tumors | Research | Radiotherapy | Risk factors | Cancer | Medical research | Brain cancer | Radiation | Clinical trials | Risk | Histology | Radiation therapy | Cancer therapies | Patients | Data bases | Oligodendroglioma | Matching | Databases | Glioma | Background radiation | Astrocytoma | Age | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Chemotherapy‐induced neuropathy
by Windebank, Anthony J and Grisold, Wolfgang
Journal of the Peripheral Nervous System, ISSN 1085-9489, 03/2008, Volume 13, Issue 1, pp. 27 - 46
Neurotoxic side effects of cancer therapy are second in frequency to hematological toxicity. Unlike hematological side effects that can be treated with... 
neurotoxins | chemotherapy agents | neurotoxicity | peripheral nervous system | prevention | Peripheral nervous system | Prevention | Neurotoxicity | Neurotoxins | Chemotherapy agents | MARIE-TOOTH-DISEASE | ACETYL-L-CARNITINE | ROOT GANGLION NEURONS | THALIDOMIDE-INDUCED NEUROPATHY | INDUCED PERIPHERAL NEUROPATHY | NEUROSCIENCES | CLINICAL NEUROLOGY | PHASE-II TRIAL | VINCRISTINE-INDUCED NEUROPATHY | ACUTE LYMPHOBLASTIC-LEUKEMIA | CISPLATIN-INDUCED TOXICITIES | OXALIPLATIN-BASED CHEMOTHERAPY | Peripheral Nervous System Diseases - diagnosis | Peripheral Nervous System Diseases - chemically induced | Animals | Antineoplastic Agents - adverse effects | Humans | Peripheral Nervous System Diseases - physiopathology | Neoplasms - physiopathology | Neoplasms - drug therapy | Platinum Compounds - adverse effects | Chemotherapy | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
by Pfreundschuh, Michael and Trümper, Lorenz and Österborg, Anders and Pettengell, Ruth and Trneny, Marek and Imrie, Kevin and Ma, David and Gill, Devinder and Walewski, Jan and Zinzani, Pier-Luigi and Stahel, Rolf and Kvaloy, Stein and Shpilberg, Ofer and Jaeger, Ulrich and Hansen, Mads and Lehtinen, Tuula and López-Guillermo, Armando and Corrado, Claudia and Scheliga, Adriana and Milpied, Noel and Mendila, Myriam and Rashford, Michelle and Kuhnt, Evelyn and Loeffler, Markus and MInT Grp and MabThera International Trial Group
Lancet Oncology, ISSN 1470-2045, 2006, Volume 7, Issue 5, pp. 379 - 391
The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young... 
ETOPOSIDE | DSHNHL | ONCOLOGY | AGGRESSIVE LYMPHOMAS | NON-HODGKINS-LYMPHOMA | RADIOTHERAPY | ELDERLY-PATIENTS | Antibodies, Monoclonal, Murine-Derived | Prognosis | Humans | Lymphoma, B-Cell - diagnosis | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Rituximab | Antibodies, Monoclonal - therapeutic use | Survival Rate | Treatment Outcome | Antineoplastic Agents - therapeutic use | Prednisone | Doxorubicin | Vincristine | Disease-Free Survival | Cyclophosphamide | Adolescent | Adult | Lymphoma, B-Cell - drug therapy | Lymphoma, Non-Hodgkin - diagnosis | Lymphoma, Non-Hodgkin - drug therapy | Medical colleges | Chemotherapy | Anthracyclines | Corticosteroids | Clinical trials | Lymphomas | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
by Schmitz, Norbert, Prof and Nickelsen, Maike, MD and Ziepert, Marita, PhD and Haenel, Mathias, MD and Borchmann, Peter, MD and Schmidt, Christian, MD and Viardot, Andreas, MD and Bentz, Martin, MD and Peter, Norma, MD and Ehninger, Gerhard, Prof and Doelken, Gottfried, Prof and Ruebe, Christian, Prof and Truemper, Lorenz, Prof and Rosenwald, Andreas, Prof and Pfreundschuh, Michael, Prof and Loeffler, Markus, Prof and Glass, Bertram, MD and German High-Grade Lymphoma Study G and German High-Grade Lymphoma Study Group (DSHNHL)
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1250 - 1259
Summary Background High-dose therapy (HDT) followed by transplantation of autologous haemopoietic stem cells is frequently done as part of first-line therapy... 
Hematology, Oncology and Palliative Medicine | THERAPY | RESPONSE CRITERIA | ONCOLOGY | PLUS ETOPOSIDE MEGACHOEP | 3-WEEKLY CHOP | PROGNOSIS | CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Rituximab | Etoposide - administration & dosage | Male | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Antimitotic agents | Chemotherapy | Stem cells | Dosage and administration | Product development | Transplantation | Lymphomas | Antineoplastic agents | Cancer | Medical informatics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Early versus late intensification for patients with high-risk Hodgkin lymphoma - 3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: Five-year results of a randomized trial on behalf of the GOELAMS Group
by Arakelyan, Nina and Berthou, Christian and Desablens, Bernard and De Guibert, Sophie and Delwail, Vincent and Moles, Marie-Pierre and Quittet, Philippe and Jais, Jean-Philippe and Colonna, Pierre and Andrieu, Jean-Marie and Gastinne, Thomas and Sénécal, Delphine and Dugay, Jacqueline and Lucas, Virginie and Casassus, Philippe and Ghandour, Christiane and Rodon, Philippe and Vilque, Jean-Pierre and Jardel, Henry and Audhuy, Bruno and Schoenwald, Michèle and Maigre, Michel and Maisonneuve, Hervé and Flesch, Michel and Grp Ouest-Est d'Etud Leucmies Et and Groupe Ouest-Est d'Etude des Leucémies et Autres Maladies du Sang and and the Groupe Ouest-Est d'Etude des Leucémies et Autres Maladies du Sang
Cancer, ISSN 0008-543X, 12/2008, Volume 113, Issue 12, pp. 3323 - 3330
BACKGROUND. The 5-year freedom from treatment failure (FFTF) rate, with treatment failure defined as the lack of post-treatment complete remission (CR),... 
Advanced stages | Intensification | Chemotherapy | Hodgkin lymphoma | advanced stages | BONE-MARROW-TRANSPLANTATION | MOPP | REGIMEN | chemotherapy | SALVAGE CHEMOTHERAPY | ABVD | intensification | ONCOLOGY | DISEASE | COMBINATION CHEMOTHERAPY | STANFORD-V | RADIOTHERAPY | Doxorubicin - therapeutic use | Dacarbazine - therapeutic use | Humans | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Male | Treatment Outcome | Combined Modality Therapy | Vinblastine - therapeutic use | Lymphatic Irradiation | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Vincristine - therapeutic use | Hodgkin Disease - drug therapy | Adult | Female | Prednisone - therapeutic use | Methylprednisolone - administration & dosage | Care and treatment | Chemotherapy, Combination | Research | Patient outcomes | Hodgkin's disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: Insights from the largest single-institutional experience
by Ayala-Ramirez, Montserrat and Feng, Lei and Habra, Mouhammed A and Rich, Thereasa and Dickson, Paxton V and Perrier, Nancy and Phan, Alexandria and Waguespack, Steven and Patel, Shreyaskumar and Jimenez, Camilo
Cancer, ISSN 0008-543X, 06/2012, Volume 118, Issue 11, pp. 2804 - 2812
BACKGROUND: The objective of this study was to evaluate the clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or... 
chemotherapy | clinical benefits | metastatic pheochromocytoma and paraganglioma | survival | MANAGEMENT | CYCLOPHOSPHAMIDE | TUMOR RESPONSE | I-131-MIBG | BIOCHEMICAL-DIAGNOSIS | ONCOLOGY | MALIGNANT PHEOCHROMOCYTOMA | DISEASE | VINCRISTINE | INHIBITOR SUNITINIB | Blood Pressure | Adrenal Gland Neoplasms - drug therapy | Paraganglioma, Extra-Adrenal - pathology | Humans | Middle Aged | Male | Paraganglioma, Extra-Adrenal - physiopathology | Pheochromocytoma - mortality | Pheochromocytoma - physiopathology | Adrenal Gland Neoplasms - physiopathology | Pheochromocytoma - drug therapy | Adrenal Gland Neoplasms - mortality | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Paraganglioma, Extra-Adrenal - drug therapy | Aged, 80 and over | Pheochromocytoma - pathology | Adult | Female | Paraganglioma, Extra-Adrenal - mortality | Adrenal Gland Neoplasms - pathology | Chromaffin cells | Chemotherapy | Care and treatment | Pheochromocytoma | Patient outcomes | Research | Diagnosis | Health aspects | Cancer | metastatic pheochromocytoma | paraganglioma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy)
by Vivekanandan, Sindu and Breene, Richard and Ramanujachar, Ramya and Traunecker, Heidi and Pizer, Barry and Gaze, Mark N and Saran, Frank and Thorp, Nicky and English, Martin and Wheeler, Kate AH and Michalski, Antony and Walker, David A and Saunders, Daniel and Cowie, Fiona and Cameron, Alison and Picton, Susan V and Parashar, Deepak and Horan, Gail and Williams, Michael V
Pediatric Blood & Cancer, ISSN 1545-5009, 12/2015, Volume 62, Issue 12, pp. 2132 - 2139
Background Historically, the 5‐year overall survival (OS) for metastatic medulloblastoma (MMB) was less than 40%. The strategy of post‐operative induction... 
HART | induction | metastatic | medulloblastoma | chemotherapy | myeloablative | Myeloablative | Chemotherapy | Metastatic | Induction | Medulloblastoma | ADJUVANT CHEMOTHERAPY | PROSPECTIVE RANDOMIZED-TRIAL | INTERNATIONAL-SOCIETY | STAGE | RADIATION-THERAPY | CHILDREN | ONCOLOGY SIOP | ONCOLOGY | VINCRISTINE | CHILDHOOD MEDULLOBLASTOMA | PEDIATRICS | CRANIOSPINAL RADIOTHERAPY | HEMATOLOGY | Follow-Up Studies | Humans | Cerebellar Neoplasms - mortality | Child, Preschool | Induction Chemotherapy | Infant | Male | Medulloblastoma - therapy | Survival Rate | Medulloblastoma - mortality | Disease-Free Survival | Adolescent | Adult | Dose Fractionation | Female | Surveys and Questionnaires | Maintenance Chemotherapy | Retrospective Studies | Cerebellar Neoplasms - therapy | Child | United Kingdom - epidemiology | Infant, Newborn | Pediatrics | Metastasis | Radiotherapy | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
by Engert, Andreas, MD and Haverkamp, Heinz, PhD and Kobe, Carsten, MD and Markova, Jana, MD and Renner, Christoph, MD and Ho, Antony, MD and Zijlstra, Josée, MD and Král, Zdenek, MD and Fuchs, Michael, MD and Hallek, Michael, MD and Kanz, Lothar, MD and Döhner, Hartmut, MD and Dörken, Bernd, MD and Engel, Nicole, MD and Topp, Max, MD and Klutmann, Susanne, MD and Amthauer, Holger, MD and Bockisch, Andreas, MD and Kluge, Regine, MD and Kratochwil, Clemens, MD and Schober, Otmar, MD and Greil, Richard, MD and Andreesen, Reinhard, MD and Kneba, Michael, MD and Pfreundschuh, Michael, MD and Stein, Harald, MD and Eich, Hans Theodor, MD and Müller, Rolf-Peter, MD and Dietlein, Markus, MD and Borchmann, Peter, MD and Diehl, Volker, MD and Arbeitsgemeinschaft Medikamentose and Swiss Grp Clinical Canc Res and German Hodgkin Study Grp and Swiss Group for Clinical Cancer Research and German Hodgkin Study Group and Arbeitsgemeinschaft Medikamentöse Tumortherapie
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Positron-Emission Tomography | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Treatment Failure | Hodgkin Disease - drug therapy | Adult | Female | Radiotherapy Dosage | Etoposide - adverse effects | Prednisone - adverse effects | Proportional Hazards Models | Etoposide - therapeutic use | Treatment Outcome | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
by Chiappella, Annalisa and Martelli, Maurizio and Angelucci, Emanuele and Brusamolino, Ercole and Evangelista, Andrea and Carella, Angelo Michele and Stelitano, Caterina and Rossi, Giuseppe and Balzarotti, Monica and Merli, Francesco and Gaidano, Gianluca and Pavone, Vincenzo and Rigacci, Luigi and Zaja, Francesco and D'Arco, Alfonso and Cascavilla, Nicola and Russo, Eleonora and Castellino, Alessia and Gotti, Manuel and Congiu, Angela Giovanna and Cabras, Maria Giuseppina and Tucci, Alessandra and Agostinelli, Claudio and Ciccone, Giovannino and Pileri, Stefano A and Vitolo, Umberto
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights